Quantcast

Latest advanced breast cancer Stories

2014-05-05 10:25:43

A new study reports that sleep efficiency, a ratio of time asleep to time spent in bed, is predictive of survival time for women with advanced breast cancer. Results show that higher sleep efficiency was significantly associated with lower mortality over the ensuing six years, an effect that remained after adjusting for baseline prognostic factors such as age, estrogen receptor status and treatments received. Mean survival was 68.9 months for efficient sleepers compared with 33.2 months...

2014-03-20 23:22:02

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112. Philadelphia, PA, and Waltham, MA (PRWEB) March 20, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Syndax Pharmaceuticals, Inc., announced today that patient recruitment has begun for E2112, a randomized phase III clinical trial of Syndax’s entinostat in treatment of patients with advanced breast cancer. The...

2012-10-10 04:03:07

Founded in 1999 By a Cancer Patient who was Facing a Dire Prognosis, the Website Offers Unique and Educational Gifts with a Touch of Morbid Humor Garland, Tx (PRWEB) October 09, 2012 Bluelips, a company that was founded in 1999 by a cancer patient who was dealing with a grim prognosis of advanced breast cancer, is currently celebrating its fourteenth year in business. The founder of the company, who successfully scared off the grim reaper, is also celebrating 14 years of life and hope....

2011-07-18 07:05:05

(Ivanhoe Newswire) -- There may be new hope for patients with advanced breast cancer. Researchers have found the use of trastuzumab, chemotherapy and surgery significantly improves survival and the time central nervous system metastases is diagnosed among patients with HER2-positive metastatic breast cancer. About 10 to 16 percent of women with advanced breast cancer develop central nervous system metastases, which means the cancer spreads to the brain. In this study, 377 of the 1,023 women...

2010-12-08 08:00:00

RIDGEFIELD, Conn. Dec. 8, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of a phase III clinical trial in the United States to investigate one of its oncology pipeline compounds, afatinib* (BIBW 2992), for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an investigational orally administered irreversible inhibitor of both the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2)...

2010-09-01 11:01:00

COLD SPRING HARBOR, N.Y., Sept. 1 /PRNewswire/ -- The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate. These reactions are available online now at ASCOPost.com and appear in the September issue of the publication. "It is...

2010-01-14 08:00:00

EMERYVILLE, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today the publication of their results from its phase 1B clinical trial of Bezielle (BZL101) for metastatic breast cancer. The results of the study are available online in Breast Cancer Research and Treatment and demonstrate that Bezielle continues to be safe and well tolerated with clinical evidence of anticancer activity in a heavily pretreated population of women diagnosed with metastatic breast...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'